CD19 CAR T Cell Therapy for Refractory Autoimmune Remission
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for autoimmune and neurological diseases, particularly those that are refractory to multiple treatments, are limited, and there is a need for effective treatments for patients who have failed standard therapies.
Innovation Solution
Administering a dose of CD19-directed genetically modified T cells expressing a chimeric antigen receptor (CAR) to patients with autoimmune and neurological diseases, targeting CD19-expressing cells to modulate the immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies are used for autoimmune and neurological diseases, then treatment options are available, but effectiveness is limited particularly in refractory cases
Solution Approach 1:
The patent applies parameter changes by modifying T cells through genetic engineering to express chimeric antigen receptors (CARs) that specifically recognize CD19. This fundamental change in the therapeutic approach transforms conventional immunosuppression into targeted cellular therapy, enabling effective treatment of refractory autoimmune and neurological diseases where conventional therapies have failed.
2Reliability
If CD19-directed CAR T cell therapy is administered, then disease activity is reduced and clinical remission is achieved, but the complexity of the treatment increases
Solution Approach 1:
The patent extracts and isolates the specific therapeutic mechanism by using CAR T cells that target only CD19-expressing cells. This extraction of the essential therapeutic function (CD19-specific targeting) from the complexity of conventional multi-drug regimens enables focused, effective treatment while reducing off-target effects and simplifying the overall treatment approach despite the advanced cellular engineering involved.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The CD19-directed CAR T cell therapy effectively reduces disease activity and achieves clinical remission in patients with severe autoimmune and neurological diseases that are refractory to multiple therapies, offering improved response and reduced toxicity compared to existing treatments.
Implementation Method 1
the T cells of the dose are positive for expression of a chimeric antigen receptor (CAR) that binds CD19
Data Source
AI summary
Provided herein are adoptive cell therapy methods and uses involving the administration of a dose of T cells expressing a CD19-directed chimeric antigen receptor for treating subjects with autoimmune and neurological disease and disorders and related methods, compositions, uses and articles of manufacture.